Accelerating product development and regulatory approval

GAP-f works to accelerate the development and regulatory approval of quality, age-appropriate medicines for children by strengthening collaboration between industry, regulators and technical partners. Through its private-sector dialogues and the WHO Paediatric Regulatory Network, GAP-f promotes formulation innovation, regulatory alignment and more efficient approval pathways, while monitoring product development and regulatory progress to anticipate bottlenecks and support timely uptake. It is also working to bridge innovation and access to novel technologies and pragmatic solutions to deliver medicines to infant and children through the Paediatric Technology Hub which will identify and assess promising formulation technologies, match and test them with priority active pharmaceutical ingredients

Resources

Development of Paediatric Medicines: Points to Consider in Formulation (TRS 1067, Annex 8)

This document aims to highlight areas of specific attention when developing medicines for children. General regulatory principles of quality for the development...